Get the Stockscreener App
7.22
0.98%
0.07
After Hours:
7.15
-0.07
-0.97%
Ataibeckley Inc stock is traded at $7.22, with a volume of 41.80M.
It is up +0.98% in the last 24 hours and up +77.40% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$7.15
Open:
$7.085
24h Volume:
41.80M
Relative Volume:
3.94
Market Cap:
$2.66B
Revenue:
$3.49M
Net Income/Loss:
$-663.48M
P/E Ratio:
-3.2251
EPS:
-2.2387
Net Cash Flow:
$-115.08M
1W Performance:
+39.65%
1M Performance:
+77.40%
6M Performance:
+98.35%
1Y Performance:
+158.78%
1-Day Range:
$7.08
$7.22
1-Week Range:
$4.81
$7.22
52-Week Range:
$2.81
$7.22
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
1 929 207 2670
Address
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
7.22 | 2.63B | 3.49M | -663.48M | -115.08M | -2.2387 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Deutsche Bank | Buy |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc.ATAI - Business Wire
Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu’s Fashion - Benzinga
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout - TradingView
Eli Lilly Expands with $2.8B Psychedelic Acquisition - Investing News Network
This ONEOK Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga
Biotech Growth says Eli Lilly's $2.8bn swoop on AtaiBeckley underlines the value of smaller drug developers - QuotedData
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time - TradingView
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies - Proactive financial news
AtaiBeckley (NASDAQ:ATAI) shares reflect merger rights valued at 14% of par - TechStock²
Eli Lilly (LLY) Is Buying AtaiBeckley To Enter Psychedelic Mental Health Treatments - simplywall.st
Canaccord Genuity Downgrades AtaiBeckley to Hold From Buy, Adjusts PT to $8 From $17 - marketscreener.com
Jefferies Downgrades AtaiBeckley to Hold From Buy, Adjusts PT to $7.50 From $10 - marketscreener.com
Eli Lilly Bets Big on Psychedelics with $3.8 Billion Takeover of AtaiBeckley - EBC Financial Group
AtaiBeckley (ATAI) After Eli Lillys Bid Still Looks Fully Valued - Yahoo Finance
Jefferies downgrades Atai stock rating to hold on Lilly buyout - Investing.com
Lilly buys Europe-rooted AtaiBeckley for up to $3.8B - European Biotechnology Magazine
Eli Lilly agrees to $3.8B psychedelic buy - Axios
Biotech Growth Trust Portfolio Company AtaiBeckley To Be Acquired By Eli Lilly - DirectorsTalk Interviews
Eli Lilly to Pay up to $3.8B for AtaiBeckley in Big Pharma’s Latest Psychedelic Foray - The Daily Upside
AtaiBeckley (ATAI) Agrees To Eli Lilly Buyout With Milestone Upside For Shareholders - simplywall.st
Why Did AAPL, ATAI, UNH Stocks Jump To 52-Week Highs Today? - Stocktwits
Top Biotech Gainers: CDNA Soars On Medicare Policy, ATAI Acquired, ABT Lifts Outlook, APLM On Watch - RTTNews
Eli Lilly (LLY.US) invests $3.8 billion to enter the psychedelic drug sector! Acquires AtaiBeckley (ATAI.US) with a 26% premium - Bitget
AtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lilly - Yahoo Finance
Why AtaiBeckley Stock Soared Today - The Motley Fool
Are ATAI, FHB, PATK Obtaining Fair Deals for their Shareholders? - Morningstar
Why AtaiBeckley Stock Soared Today - The Motley Fool
Lilly offers up to $3.8 billion for AtaiBeckley in bet on ‘God molecule’ found in toad venom - drugdiscoverytrends.com
Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion - The Motley Fool
Lilly to enter psychedelics field with $3.8B AtaiBeckley buy - FirstWord PHARMA
Lilly to buy psychedelic-drug firm AtaiBeckley - Chemical & Engineering News
Nasdaq slides as chip selloff drags Wall Street lower - Proactive financial news
Recon: Lilly to buy psychedelic developer AtaiBeckley for up to $3.8B; FDA approves Merck’s novel cholesterol drug - RAPS
Eli Lilly Buys AtaiBeckley in $3.8 Billion Deal - TradingView
AtaiBeckley Soars as Eli Lilly Agrees to $2.8 Billion Buyout - TradingView
Market movers: AtaiBeckley, UnitedHealth Group, Abbott Laboratories, Medicus Pharma… - Proactive financial news
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of AtaiBeckley Inc. (NASDAQ: ATAI) - PR Newswire
AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline - Seeking Alpha
Eli Lilly Acquires Psychedelics Specialist AtaiBeckleyWhat Investors Should Know (LLY) - Seeking Alpha
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug - Yahoo Finance
Lilly Expands Its Mind to Psychedelics With $2.8B AtaiBeckley Acquisition - MedCity News
AtaiBeckley Stock Is Soaring 34% as Eli Lilly Agrees to Buy Psychedelic Drugmaker -- Barrons.com - Moomoo
Pharma giant Eli Lilly enters psychedelics space with AtaiBeckley takeover - Mugglehead Investment Magazine
Lilly to Buy Psychedelic Firm AtaiBeckley for Up to $3.8 Billion - marketscreener.com
AtaiBeckley (ATAI) Sees 32.9% Surge in Stock Price - GuruFocus
Eli Lilly Changed Depression Care With Prozac. Now It's Betting on Psychedelics with AtaiBeckley Acquisition - International Business Times
Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock - Barchart.com
Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover - Pharmaceutical Technology
Lilly acquiring firm developing psychedelic depression treatments for up to $3.8M - Inside INdiana Business
Eli Lilly buys psychedelic drugs company AtaiBeckley for $3.8bn - The Times
Latham & Watkins Represents AtaiBeckley in Sale to Lilly - Latham & Watkins LLP
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):